Gemcitabine-induced pancreatic cancer cell death is associated with MST1/cyclophilin D mitochondrial complexation

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Pancreatic adenocarcinoma is highly aggressive with poor survival.
• Gemcitabine is used post-surgery but its cell death mechanisms are unclear.
• Chemo-resistance factors require further characterization.

Purpose of the Study:

• Investigate the roles of mammalian sterile 20-like kinase 1 (MST1) and cyclophilin D (Cyp-D) in gemcitabine-induced pancreatic cancer cell death.
• Elucidate the molecular mechanisms underlying gemcitabine sensitivity and resistance.

Main Methods:

• Assessed MST1 and Cyp-D expression in gemcitabine-resistant vs. sensitive cells.
• Utilized in vitro models with gemcitabine treatment, antioxidants (NAC), shRNA silencing, and overexpression.
• Examined mitochondrial translocation and complex formation of MST1 and Cyp-D.
• Employed cyclosporin A (CsA) as a Cyp-D inhibitor.

Main Results:

• MST1 and Cyp-D expression were lower in gemcitabine-resistant cells.
• Gemcitabine activated MST1 via reactive oxygen species (ROS).
• Gemcitabine induced MST1 mitochondrial translocation and complex formation with Cyp-D.
• Silencing MST1 or Cyp-D reduced gemcitabine-induced cell death; overexpression increased it.
• CsA inhibited MST1/Cyp-D complexation and cell death.

Conclusions:

• Gemcitabine-induced pancreatic cancer cell death necessitates MST1/Cyp-D mitochondrial complexation.
• MST1 and Cyp-D are critical mediators of gemcitabine efficacy.
• Targeting the MST1/Cyp-D pathway may overcome gemcitabine resistance in pancreatic cancer.